title: In vitro efficacy of newly designed vancomycin-based microparticles.
abstract: OBJECTIVE
  To compare the in vitro bactericidal and anti-adhesion properties of vancomycin-based microparticles and lyophilized vancomycin and estimate their relevance to perioperative antibiotic prophylaxis and endophthalmitis prevention.
  
  
  METHODS
  University research laboratory, Lyon, France.
  
  
  METHODS
  The bactericidal and anti-adhesion properties of a newly designed drug-delivery system were assessed on Staphylococcus epidermidis clinical strain N890074 containing the intercellular adhesion locus ica. Lyophilized vancomycin at 20 mug/mL was used as a standard. The new drug-delivery system, designed for the study, consisted of sterile, biocompatible, and biodegradable microparticles with continuous release of vancomycin. To obtain bacterial killing and anti-adhesion curves, experiments were first performed in a bacterial suspension containing 1000 colony-forming units per milliliter. Experiments were then performed with intraocular lenses incubated in the suspension. Efficacy was investigated by bacterial counts and scanning electron microscopy observations.
  
  
  RESULTS
  The bactericidal and anti-adhesion effects of vancomycin-based microparticles started after 3 hours (P<.002) and 1 hour (P<.001), respectively, and of lyophilized vancomycin, after 1 hour (P = .004) and 1 hour (P<.001), respectively. There was no difference between the 2 forms of vancomycin in the bactericidal effect starting at 21 hours and the anti-adhesion effect starting at 6 hours (P>.05).
  
  
  CONCLUSIONS
  The newly designed vancomycin-based microparticles showed relevant antibacterial and anti-adhesion properties after releasing a sufficient antibacterial quantity, proving that vancomycin remains efficient after undergoing the encapsulation process.
authors.affiliation: Laboratoire d'Automatique et de Génie des Procédés, Villeurbanne, France. hachicha@lagep.cpe.fr
authors.forename: Walid
authors.initials: W
authors.lastname: Hachicha
authors.forename: Hatem
authors.initials: H
authors.lastname: Fessi
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Casoli-Bergeron
authors.forename: Mi-Yeon
authors.initials: MY
authors.lastname: Lee
authors.forename: Chiraz
authors.initials: C
authors.lastname: Jaafar
authors.forename: Alexandra
authors.initials: A
authors.lastname: Clayer-Montembault
authors.forename: Carole
authors.initials: C
authors.lastname: Burillon
authors.forename: Jean
authors.initials: J
authors.lastname: Freney
authors.forename: Laurent
authors.initials: L
authors.lastname: Kodjikian
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019072:Antibiotic Prophylaxis; D001422:Bacterial Adhesion / Q000187:drug effects*; D001672:Biocompatible Materials; D015169:Colony Count, Microbial; D004337:Drug Carriers; D009877:Endophthalmitis / Q000517:prevention & control; D019344:Lactic Acid; D007910:Lenses, Intraocular / Q000382:microbiology*; D008855:Microscopy, Electron, Scanning; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000254:growth & development; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D004337:Drug Carriers; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D014640:Vancomycin